Development of Factor VIII:C Antibodies in Dogs With Hemophilia A (Factor VIII:C Deficiency)

• Published in: Blood 1984-02, Vol.63 (2), p.451-456
• Main Authors: Giles, Alan R., Tinlin, Shawn, Hoogendoorn, Hugh, Greenwood, Penny, Greenwood, Ronald
• Format: Article
• Language: English
• Subjects: Animals; Antibody Specificity; Antigens - immunology; Autoantibodies - immunology; Biological and medical sciences; Bleeding Time; Breeding; Dogs; Factor VIII - immunology; Factor VIII - therapeutic use; Female; Hemarthrosis - drug therapy; Hematologic and hematopoietic diseases; Hemophilia A - genetics; Hemophilia A - immunology; Male; Medical sciences; Platelet diseases and coagulopathies; Swine - immunology
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V63.2.451.451

Classic hemophilia A (factor VIII:C deficiency) was diagnosed in a miniature Schnauzer dog and a breeding program established. Inbreeding and crossbreeding produced 16 hemophilic animals. All were initially treated with canine cryoprecipitate, as required, for sporadic hemorrhagic events. Five animals developed potent antibodies to canine factor VIII:C. All were the offspring of obligate carriers, resulting from the mating of a hemophilic purebred miniature Schnauzer male to a normal female Brittany spaniel. The mean age at first treatment and factor VIII exposure at the time of inhibitor development was 10.3 wk and 286.3 U, respectively. The remaining hemophilic animals have not developed antibodies, despite receiving a mean factor VIII dosage of 1.5 x 103 U. This group includes animals derived from a mating between the same purebred miniature Schnauzer hemophilic male and a purebred miniature Schnauzer carrier female. In each case, the antibodies recognize both canine and human but not porcine VIII:C. They are nonprecipitating IgG immunoglobulins. Following inhibitor development, infusion of canine cryoprecipitate was hemostatically ineffective and factor VIII:C recovery at 30 min was negligible. Infusion of a concentrate of porcine factor VIII resulted in a correction of the hemostatic defect and optimal factor VIII:C recovery. All animals receiving porcine factor VIII:C subsequently developed antibodies to this protein. The chance occurrence of this complication should facilitate further studies directed at elucidating the pathogenesis and management of hemophilia complicated by the development of antibodies to factor VIII:C.